1 / 13

Rash and Low T2* MRI in a Paediatric Thalassaemia Patient

Rash and Low T2* MRI in a Paediatric Thalassaemia Patient. Patient Presentation. 9 1/2-year-old male patient with - thalassaemia Patient has been transfused with 1 unit every 3 weeks (0.46 mg/kg/d) since age 1 year

vernados-karan
Download Presentation

Rash and Low T2* MRI in a Paediatric Thalassaemia Patient

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rash and Low T2* MRI in a Paediatric Thalassaemia Patient

  2. Patient Presentation • 9 1/2-year-old male patient with -thalassaemia • Patient has been transfused with 1 unit every 3 weeks (0.46 mg/kg/d) since age 1 year • At age 3 years, the patient began receiving desferrioxamine and is currently receiving desferrioxamine 40 mg/kg/d • Usually doses > 40 mg/kg/d are not recommended in paediatric patients

  3. Thresholds for Parameters Used to Evaluate Iron Overload Parameter Normal Iron Overloaded State Mild Moderate Severe LIC (mg Fe/g dw) <1.2 3–7 >7 >15 Serum ferritin (ng/mL) <300 >1000 to <2500 >2500 Transferrin saturation (%) 20–50 >50 T2* (ms) >20 14–20 8–14 <8 Alanine aminotransferase (U/L) <250 >250 Labile plasma iron (μM) 0–0.4 >0.4 Increased risk of complications Increased risk of cardiac disease Courtesy of A. Taher, MD.

  4. Response to DesferrioxamineBaseline Results aIndicating cardiac iron prevalence

  5. Question What should the next step be? A. Continue on desferrioxamine at current dose B. Increase dose of desferrioxamine to >50 mg/kg/d C. Switch to deferiprone 100 mg/kg/d D. Switch to deferasirox 30 mg/kg/d

  6. Choice of Chelator • Patient is already on a high dose of desferrioxamine and a higher dose at his age is contraindicated • Although deferiprone is approved for patients with thalassaemia when desferrioxamine is inadequate, starting dose is 75 mg/kg/d and doses >100 mg/kg/d are not recommended; TID dosing may pose difficulties for a patient his age • Usual starting dose of deferasirox is 20 mg/kg/d, but 10 mg and 30 mg may also be used; once-daily oral administration makes deferasirox attractive for use in children

  7. Deferasirox Dosing • Recommended starting dose and modifications to treatment with deferasirox are the same in children and adults • In clinical studies, 20 or 30 mg/kg/d resulted in overall maintenance or reduction of liver iron concentration, respectivelya • Starting dose of 10 mg/kg/d was not sufficient to achieve a negative iron balance in heavily transfused patients • Patient began treatment with deferasirox30 mg/kg/d aStudy 107 Cappellini MD, et al. Blood. 2006;107:3455-3462.

  8. Question At 1 month, patient developed a moderate-to-severe skin rash. How should this rash be managed? • Reduce dose, then gradually increase dose to prior level when rash resolves B. Interrupt drug, then reintroduce at lower level when rash resolves, gradually escalating to target level C. Switch back to desferrioxamine or consider deferiprone

  9. Resolution of Rash • Drug treatment interrupted due to moderate-to-severe skin rash • After 1 week, patient was restarted on reduced drug dose (20 mg/kg/d) and rash resolved • After 2 months, dose was successfully increased to 30 mg/kg/d • Minor dose adjustments were made periodically over the next 3 years in response to serum ferritin levels

  10. Skin Rash Treatment Algorithm • Mild-to-moderate rash can be managed without treatment interruption • More serious rash necessitates treatment interruption. Deferasirox should be reintroduced at a lower dosage after rash has resolved, with gradual dose escalation • With severe rash, deferasirox should be interrupted, then reintroduced at a lower dose, possibly in combination with an oral steroid, after rash has resolved. Deferasirox dosage can then be gradually increased.

  11. Response to Treatment • Serum ferritin levels decreased steadily over next 3 years to <500 ng/mL • Liver iron concentration decreased to5.0 mg/g dry weight • T2* readings increased steadily, from 10.6 ms to 17.0 ms • Patient then received a successful bone marrow transplant

  12. Dose Adjustmentsand Serum Ferritin Levels Serum ferritin levels during treatment with deferasirox Serum Ferritin (ng/mL) Deferasirox Dose (mg/kg/d) Month

  13. Conclusions • Deferasirox at appropriate doses results in continued reduction in serum ferritin levels • Reduced cardiac iron burden in children, as measured by increased T2*, is also achieved with appropriate doses of deferasirox • Skin rashes can be managed effectively, in many cases without interruption of treatment • In this patient, dose reduction to 20 mg/kg/d was sufficient for resolution of rash • Dose was then increased again to previous 30 mg/kg/d and serum ferritin levels fell continuously for the next 3 years

More Related